|

Fam-Trastuzumab Deruxtecan-Nxki (TDxD) Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: Enhertu

Pipeline

Phase 1: 1Phase 2: 1

Top Sponsors

  • Fox Chase Cancer Center1
  • American Society of Clinical Oncology1

Indications

  • Cancer2
  • HER2 Gene Mutation1
  • Gastrointestinal Cancer1
  • Advanced Solid Tumors1
  • Lymphoma, Non-Hodgkin1

Birmingham, Alabama1 trial

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

University of Alabama at Birmingham Comprehensive Cancer Center

Phase 2

Palo Alto, California1 trial

Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients

Stanford Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.